Trial reportCNS drugs2008
Oral zolmitriptan in the short-term prevention of menstrual migraine: a randomized, placebo-controlled study.
Trial report in CNS drugs, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 3 syntheses or guidelines pooled it, 53 citations in OpenAlex.
- Acute and preventive treatment of menstrual migraine: a meta-analysis.The journal of headache and pain · 2024Pooled it
- Triptans in prevention of menstrual migraine: a systematic review with meta-analysis.The journal of headache and pain · 2013Pooled it
- Guideline
- Framing and Management of Migraines in Women: An Expert Opinion on Challenges, Current Approaches, and Future Multidisciplinary Perspectives.Healthcare (Basel, Switzerland) · 2025Article
- Acute and Preventive Management of Migraine during Menstruation and Menopause.Journal of clinical medicine · 2021Review
- Management of Menstrual Migraine.Current neurology and neuroscience reports · 2020Review
- A review of the use of frovatriptan in the treatment of menstrually related migraine.Therapeutic advances in neurological disorders · 2013Article
- Preventive treatment in migraine and the new US guidelines.Neuropsychiatric disease and treatment · 2013Article
- Treatment of perimenstrual migraine with triptans: an update.Current pain and headache reports · 2012Review
- Italian guidelines for primary headaches: 2012 revised version.The journal of headache and pain · 2012Article
- Are the current IHS guidelines for migraine drug trials being followed?The journal of headache and pain · 2010Review
- Prevention and treatment of menstrual migraine.Drugs · 2010Review
- Management of menstrual migraine: a review of current abortive and prophylactic therapies.Current pain and headache reports · 2010Review
- Menstrual migraine: therapeutic approaches.Therapeutic advances in neurological disorders · 2009Article
- Clinical aspects of perimenstrual headaches.Current pain and headache reports · 2009Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo evaluate the efficacy and tolerability of oral zolmitriptan as a short-term preventative therapy for menstrual migraine.
methodsThis was a randomized, double-blind, parallel group, placebo-controlled, multicentre, two-phase study. The results of the second phase are reported here (the first phase evaluated zolmitriptan in the acute treatment of menstrual migraine and is reported elsewhere). Women who successfully completed phase I (with either a positive or negative outcome, and who still fulfilled the inclusion criteria) were randomized to zolmitriptan 2.5 mg oral tablet three times daily, zolmitriptan 2.5 mg twice daily or placebo three times daily. Patients were treated for three consecutive menstrual cycles, starting 2 days prior to the expected onset of menses, for 7 days in total.
resultsTwo hundred and fifty-three patients completed phase I and were eligible for phase II. The intention-to-treat population comprised 244 patients (zolmitriptan three times daily [n = 83]; zolmitriptan twice daily [n = 80]; placebo [n = 81]). Both zolmitriptan regimens demonstrated superior efficacy versus placebo, as measured by the proportion of patients with a >or=50% reduction in the frequency of menstrual migraine attacks (zolmitriptan three times daily [58.6%], p = 0.0007 vs placebo; zolmitriptan twice daily [54.7%], p = 0.002 vs placebo; placebo three times daily [37.8%]). The mean frequency of breakthrough migraine attacks per menstrual cycle was reduced accordingly. Fewer breakthrough attacks were treated with escape medication in the zolmitriptan three times daily (61.6% of attacks; p = 0.0004 vs placebo) and twice daily (60.7%; p = 0.0055 vs placebo) treatment groups than in the placebo group (74.4%). Short-term preventative therapy with zolmitriptan was well tolerated.
conclusionZolmitriptan 2.5 mg oral tablet is effective and well tolerated as a short-term preventative therapy for menstrual migraine attacks.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.